AA
AVBP icon

ALPS Advisors’s ArriVent BioPharma AVBP Stock Holding History

ALPS Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
47,074
+11,088
+31% +$327K 0.01% 581
2026
Q1 		$830K Buy
35,986
+2,090
+6% +$47.2K ﹤0.01% 609
2025
Q4 		$682K Buy
+33,896
New +$706K ﹤0.01% 659
2025
Q2 		– Sell
-25,167
Closed -$465K – 1063
2025
Q1 		$465K Sell
25,167
-2,085
-8% -$51K ﹤0.01% 603
2024
Q4 		$726K Sell
27,252
-181
-0.7% -$5.2K ﹤0.01% 552
2024
Q3 		$645K Buy
27,433
+1,294
+5% +$29.4K ﹤0.01% 583
2024
Q2 		$485K Buy
+26,139
New +$466K ﹤0.01% 581

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ALPS Advisors's AVBP Position: Q2 2026 in Review

ALPS Advisors increased its ArriVent BioPharma (AVBP) stake by 31% in Q2 2026, buying an estimated $327K and bringing the position to 47,074 shares worth $1.64M. The position accounts for 0.01% of the portfolio, ranked #581.

ALPS Advisors first reported a position in AVBP in Q2 2024 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • ALPS Advisors held 47,074 shares of ArriVent BioPharma worth $1.64M as of Q2 2026.
  • ALPS Advisors bought 11,088 ArriVent BioPharma shares in Q2 2026, an estimated $327K.
  • ArriVent BioPharma made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #581 holding.
  • ALPS Advisors first reported a position in ArriVent BioPharma in Q2 2024 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.